The CJC-1295 research timeline begins decades before the compound itself existed — because the story of this GHRH analog is inseparable from the story of growth hormone-releasing hormone research as a whole. CJC-1295, a tetra-substituted GHRH(1-29) analog with an albumin-binding Drug Affinity Complex (DAC), emerged in the early 2000s as a long-acting answer to GHRH’s minutes-long half-life. But the milestones that made it possible — the isolation of human GHRH, sermorelin’s approved-product history, the first human CJC-1295 studies — stretch back to the 1980s and forward to today. This CJC-1295 research timeline walks through those milestones in chronological order, citing only published literature and the public regulatory record. It is a history of research, not a guide to use: it contains no dosage information, no administration instructions, and no medical advice.
Research-use-only disclaimer: CJC-1295 has never been FDA-approved and is handled as a research compound for laboratory and scientific investigation only. This article is an educational literature history. It contains no dosage information, no administration instructions, no efficacy claims for humans, and no medical advice.
How to Read This CJC-1295 Research Timeline
Every entry in this CJC-1295 research timeline is a published milestone: a study, a regulatory event, or a documented development. Where a finding is described, the description is hedged — “the study reported,” “published summaries describe” — because a timeline should track what the literature recorded, not settle what it proved. Dates come from publication records and regulatory documents; where the exact year of a corporate development is approximate, the text says so.
The CJC-1295 Research Timeline
1982 — Human GHRH is isolated and sequenced
The CJC-1295 research timeline opens with the molecule that made everything else possible. Published reports place the isolation and sequencing of human growth hormone-releasing hormone in 1982, by research teams including Guillemin’s group (the full account is reviewed in Thorner, 2008). Once the native hormone’s 44-amino-acid sequence was known, researchers could begin building synthetic fragments and analogs — the entire engineering lineage that would eventually produce CJC-1295.
1997 — Sermorelin (Geref) gains FDA approval
The FDA approves sermorelin acetate (Geref), a synthetic analog of the GHRH(1-29) fragment, for diagnosis of growth hormone deficiency and treatment of idiopathic GH deficiency in prepubertal children. Sermorelin becomes the first GHRH analog with an approved-product clinical record — a reference point against which every later compound in the CJC-1295 research timeline, including CJC-1295 itself, would implicitly be measured.
Early 2000s — ConjuChem develops CJC-1295
According to published summaries, the biotechnology company ConjuChem develops CJC-1295 in the early 2000s: a tetra-substituted GHRH(1-29) analog carrying four amino acid substitutions for enzyme resistance, plus a Drug Affinity Complex — a maleimidopropionic acid linker that covalently binds serum albumin. The albumin-binding design is the key innovation: it creates a circulating depot intended to stretch the compound’s persistence from minutes to days.
2006 — First human data: Teichman et al., JCEM
Teichman SL and colleagues publish “Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone-releasing hormone, in healthy adults” in the Journal of Clinical Endocrinology & Metabolism (2006;91(3):799–805). This Phase I study is the first published human trial of CJC-1295, reporting prolonged GH and IGF-I stimulation after administration — the clinical debut of the DAC concept and the most-cited entry in the CJC-1295 research timeline.
2006 — Pulsatility finding: Ionescu & Frohman, JCEM
Ionescu M and Frohman LA publish “Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GHRH analog” (JCEM, 2006;91(12):4792–4797). The study reports that even under continuous GHRH-receptor stimulation, the underlying pulsatile pattern of GH secretion persists — trough levels rise, but pulse number and height are preserved. This finding becomes one of the most discussed features of the CJC-1295 literature: sustained exposure without loss of the natural rhythm.
2006 — Preclinical breadth: Alba et al., AJP-Endo
Alba M and colleagues publish a study in the American Journal of Physiology – Endocrinology and Metabolism (2006) reporting that once-daily CJC-1295 normalizes growth in the GHRH-knockout mouse — a model lacking endogenous GHRH signaling. The result extends the CJC-1295 research timeline into preclinical models, suggesting the compound’s activity persists across species and experimental systems.
2007 — A parallel GHRH story: tesamorelin Phase III data
Falutz J and colleagues publish Phase III results for tesamorelin (then coded TH9507) — a different GHRH analog — in the New England Journal of Medicine (2007;357(23):2359–2370), reporting metabolic effects in patients with HIV. Tesamorelin is not CJC-1295, but its progress belongs in this CJC-1295 research timeline as context: it shows the GHRH-analog field advancing on a parallel track, and it would go on to achieve what CJC-1295 never did — FDA approval.
2008 — Geref discontinued for commercial reasons
EMD Serono announces the discontinuation of Geref Diagnostic (sermorelin), effective October 2008, because the active ingredient is no longer being manufactured — a business decision, with the FDA listing the withdrawal as for reasons other than safety or effectiveness. The event closes the approved-product chapter of the GHRH-analog story and leaves CJC-1295 and its relatives entirely in the research domain.
2009 — Extended human profiling: Sackmann-Sala et al.
Sackmann-Sala L and colleagues publish in Growth Hormone & IGF Research (2009), describing activation of the GH/IGF-1 axis by CJC-1295 along with changes in serum protein profiles in healthy adults. This study broadens the CJC-1295 research timeline beyond the GH axis itself, documenting how sustained GHRH-receptor stimulation registers across circulating proteins — the most detailed human pharmacodynamic portrait of the compound published to that point.
2010 — Tesamorelin approved; CJC-1295’s path diverges
The FDA approves tesamorelin (Egrifta) on November 10, 2010, for HIV-associated lipodystrophy. With this decision, the GHRH-analog field splits permanently: tesamorelin enters the regulated drug world with Phase III evidence, while CJC-1295 — despite its published human data — remains a research compound with no approval and no further large-scale clinical program announced in the literature. The divergence is the single most important regulatory fact in the later CJC-1295 research timeline.
2010s–present — The research-compound era
No new large clinical program for CJC-1295 appears in the published literature after 2010. The compound continues to be studied and discussed as a research chemical — including its no-DAC form (modified GRF 1-29), a distinct short-acting compound often used in research settings — but the peer-reviewed human evidence base effectively stops growing. The CJC-1295 research timeline thus has a distinctive shape: a burst of high-quality early data, then a long plateau of research-compound status.
Timeline honesty check: Notice what this CJC-1295 research timeline does not contain: no Phase II/III program for CJC-1295 itself, no approval milestone, and no large-scale efficacy data. The most-cited human studies are Phase I and small pharmacodynamic studies. A timeline that omitted that gap would be misrepresenting the literature.
CJC-1295 Research Timeline: Milestone Summary
| Year | Milestone | Significance |
|---|---|---|
| 1982 | Human GHRH isolated and sequenced | Template for all GHRH analogs identified |
| 1997 | Sermorelin (Geref) FDA-approved | First approved GHRH analog; clinical reference point |
| Early 2000s | CJC-1295 developed by ConjuChem | DAC albumin-binding design created |
| 2006 | Teichman et al., JCEM — first human trial | Prolonged GH/IGF-I stimulation reported |
| 2006 | Ionescu & Frohman, JCEM — pulsatility study | GH pulses preserved under continuous stimulation |
| 2006 | Alba et al. — GHRH-knockout mouse study | Preclinical cross-species activity reported |
| 2007 | Tesamorelin Phase III published (NEJM) | Parallel GHRH-analog track advances |
| 2008 | Geref discontinued (commercial) | Approved-product era ends |
| 2009 | Sackmann-Sala et al. — axis + protein profiling | Detailed human pharmacodynamic portrait |
| 2010 | Tesamorelin FDA-approved (Egrifta) | Regulatory paths diverge permanently |
| 2010s–now | Research-compound era | Literature plateau; no new clinical program |
What the Timeline Reveals About the Compound
Read as a whole, the CJC-1295 research timeline tells a story that is common in peptide research but rarely laid out this plainly. The chemistry was ambitious and the early human data were genuinely interesting — prolonged stimulation, preserved pulsatility, axis-wide effects. But interesting early data are not a development program, and no development program followed. The compound’s literature footprint is therefore frozen in time: a handful of well-executed early studies, a regulatory record that ends at “research compound,” and a parallel success story (tesamorelin) that shows what the alternative path looked like.
For researchers, the practical reading of the CJC-1295 research timeline is this: the compound is best understood as a well-characterized research tool with a defined early evidence base, not as an unfinished drug awaiting completion. The timeline supports the first description and does not support the second.
Citing this history: The key primary sources in the CJC-1295 research timeline are Teichman et al. (JCEM, 2006), Ionescu & Frohman (JCEM, 2006), Alba et al. (Am J Physiol Endocrinol Metab, 2006), and Sackmann-Sala et al. (Growth Horm IGF Res, 2009). Researchers can locate these through PubMed. Background on the parent hormone is at Wikipedia’s GHRH page, and compound overviews at CJC-1295 and Sermorelin.
Related Research Reading on This Site
Our other guides apply the same literature-history approach to different compound families. The Selank vs Semax research comparison traces two neurotropic research peptides, and our format guides — Selank nasal spray research and Semax nasal spray research — cover delivery formats studied in research settings. Compounds from those guides are available as research materials: Semax 10mg and Selank 10mg.
CJC-1295 Research Timeline: Key Takeaways
A burst of early data, then a permanent plateau
The CJC-1295 research timeline concentrates its human evidence in 2006–2009: a Phase I trial, a pulsatility study, and a pharmacodynamic profiling study. Nothing of comparable scale followed. Researchers should treat the compound as a well-characterized early-stage research tool, not as a compound with a growing evidence base. (Research framing only — not a human-use recommendation.)
2010 is the fork in the road
Tesamorelin’s 2010 FDA approval and CJC-1295’s continued research-compound status mark the permanent divergence of two GHRH-analog paths. Any comparison of the compounds must respect that fork: one has regulated-drug evidence for a specific indication, the other has early research data only. (Research framing only.)
CJC-1295 Research Timeline: Final Research Notes
The CJC-1295 research timeline is, in the end, a reminder that scientific interest and clinical development are different things. The compound attracted genuine research attention — the DAC design was clever, the early studies were well executed, and the pulsatility finding was scientifically interesting. But attention did not become a program, and the timeline simply stops advancing after 2010. That is not a judgment on the chemistry; it is what the publication record shows.
For anyone encountering CJC-1295 in research-product contexts, this CJC-1295 research timeline is the antidote to hype in either direction: the compound is neither a forgotten miracle nor a proven failure. It is a research compound with a documented, bounded, early history — and now you know exactly where the boundaries are.
CJC-1295 Research Timeline: Frequently Asked Questions
Quick answers about the history of CJC-1295 research — all in research framing.
When was CJC-1295 first studied in humans?
The first published human trial of CJC-1295 was Teichman et al., published in the Journal of Clinical Endocrinology & Metabolism in 2006 (91(3):799–805). This Phase I study reported prolonged growth hormone and IGF-I stimulation in healthy adults and is the opening clinical entry in the CJC-1295 research timeline.
What did the 2006 pulsatility study find?
Ionescu and Frohman (JCEM, 2006) reported that pulsatile growth hormone secretion persisted during continuous CJC-1295 stimulation — trough GH levels rose while pulse number and height were preserved. The finding is one of the most discussed in the CJC-1295 research timeline because it showed sustained exposure without loss of the natural secretory rhythm.
Was CJC-1295 ever FDA-approved?
No. CJC-1295 has never been FDA-approved, and no large-scale Phase II/III program for it appears in the published literature. The related GHRH analog tesamorelin was approved in 2010 (Egrifta) for HIV-associated lipodystrophy — a different compound with its own trial program. The FDA’s drug information pages document what approval status means.
Who developed CJC-1295?
Published summaries attribute CJC-1295’s development to ConjuChem in the early 2000s. The key innovation was the Drug Affinity Complex: a maleimidopropionic acid linker that covalently binds serum albumin, creating a circulating depot intended to extend the compound’s persistence from minutes to days.
Why did CJC-1295 research stop advancing after 2010?
The published literature records no new large clinical program for CJC-1295 after the 2006–2009 studies. The reasons are not documented in the peer-reviewed record — corporate development decisions of that kind rarely are. What the CJC-1295 research timeline shows is the outcome: a research compound whose human evidence base froze in time while a parallel GHRH analog (tesamorelin) completed development.
What is the most-cited study in the CJC-1295 literature?
The Teichman et al. 2006 Phase I study (JCEM 91(3):799–805) is the most-cited human study, followed closely by Ionescu & Frohman 2006 on pulsatility and Sackmann-Sala et al. 2009 on GH/IGF-1 axis and serum protein profiling. Together these three studies constitute the core of the published human evidence in the CJC-1295 research timeline; all are locatable via PubMed.
1 Comment
James Parker
A well-structured research timeline helps readers understand how scientific interest in CJC-1295 has evolved over time. Exploring the history of cjc growth hormone also provides valuable context for understanding its potential mechanisms and the direction of future studies.